Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/27/2025

Erythromelalgia Treatment Guidelines

Initial Management

  • The American College of Physicians recommends implementing lifestyle modifications to minimize flares while maintaining normal activities, including avoiding triggers such as excessive heat and strenuous exercise, and limiting cooling measures to prevent tissue damage 3
  • Limiting cooling measures, such as ice/water immersion, to 10 minutes, maximum 4 times daily, can help prevent tissue damage 4, 5

First-Line Treatments

  • The Mayo Clinic recommends using lidocaine patches (4% OTC or 5% prescription) applied to affected areas for 12-24 hours for pain management 1
  • Compounded amitriptyline-ketamine mixture applied to affected areas up to 3 times daily can be used for pain management 1
  • Capsaicin cream (0.025-0.075%) applied 3-4 times daily for 6 weeks can be used for pain management, with a warning to patients about the initial burning sensation 6
  • Compounded midodrine 0.2% applied 3 times daily is an evidence-based preferred treatment for erythema management 5

Second-Line Treatments

  • Aspirin 325mg daily for at least 1 month is particularly effective for secondary erythromelalgia associated with myeloproliferative disorders, with a strength of evidence based on clinical trials 2
  • Other NSAIDs, such as ibuprofen, indomethacin, naproxen, and piroxicam, can be used for aspirin-allergic patients 2
  • Corticosteroids can be considered early in the disease course to prevent irreversible nociceptive remodeling 2

Third-Line Treatments

  • Referral to a comprehensive pain rehabilitation center for multidisciplinary management can be considered for refractory cases 5
  • Intravenous lidocaine can be considered for refractory cases, with a note on safety concerns including neurologic effects 2
  • Ketamine infusion can be considered for refractory cases, with limited evidence and controversy due to adverse effects 2

Special Considerations

  • Treatment for secondary erythromelalgia due to myeloproliferative disorders should focus on addressing the underlying condition, with a high strength of evidence based on clinical trials 1
  • Topical therapies are generally preferred due to limited side effects compared to systemic options, with a moderate strength of evidence based on clinical trials 5

Common Pitfalls to Avoid

  • Excessive cooling with ice water or fans can lead to tissue damage, ulcerations, and worsening symptoms when discontinued, with a high strength of evidence based on clinical trials 3
  • Discontinuing treatments too quickly before adequate trial periods (4 weeks for topicals, 3-4 months for systemic medications) can lead to inadequate management of symptoms, with a moderate strength of evidence based on clinical trials 5